Forxiga safety under review in 1,000 vietnamese patients
NCT ID NCT07210307
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 29 times
Summary
This study tracked the safety of the diabetes drug Forxiga (dapagliflozin) in over 1,000 adults with type 2 diabetes across eight hospitals in Vietnam. Researchers monitored side effects for 24 weeks to meet local regulatory requirements. The goal was to gather real-world safety data, not to test new treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY OUTCOMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
HCMC Heart Institute
Ho Chi Minh City, Vietnam
Conditions
Explore the condition pages connected to this study.